InsiderTrades.com logo
Andrew Reardon net worth and biography
  • Phone
  • Email
  • Website

Andrew Reardon Biography and Net Worth

Chief Legal Officer of Ligand Pharmaceuticals

Andrew Reardon is Ligand’s Chief Legal Officer, a role that he has held since 2022. He was previously a Vice President and Special Counsel to the company.

Before joining Ligand, Mr. Reardon served as Chief Legal Officer at HealthCare Royalty Partners, a global healthcare investment firm, for more than 10 years. Prior to HealthCare Royalty Partners, Mr. Reardon was with the international law firm Willkie Farr & Gallagher, where he focused on corporate transactions, including finance and mergers and acquisitions. He also served as an executive with Citibank from 1997 to 2000.

Mr. Reardon earned his JD from the University of Iowa College of Law, graduating with High Distinction and receiving the Alan I. Widiss Faculty Scholar Award. He also received his BA with honors from the State University of New York College at Old Westbury. Mr. Reardon is a former US Army National Guard infantry officer.

What is Andrew Reardon's net worth?

The estimated net worth of Andrew Reardon is at least $2.18 million as of September 23rd, 2024. Mr. Reardon owns 22,534 shares of Ligand Pharmaceuticals stock worth more than $2,178,362 as of April 8th. This net worth evaluation does not reflect any other assets that Mr. Reardon may own. Additionally, Mr. Reardon receives a salary of $614,870.00 as Chief Legal Officer at Ligand Pharmaceuticals. Learn More about Andrew Reardon's net worth.

How old is Andrew Reardon?

Mr. Reardon is currently 49 years old. There are 3 older executives and no younger executives at Ligand Pharmaceuticals. The oldest executive at Ligand Pharmaceuticals is Mr. Scott M. Plesha, Chief Executive Officer, who is 59 years old. Learn More on Andrew Reardon's age.

What is Andrew Reardon's salary?

As the Chief Legal Officer of Ligand Pharmaceuticals Incorporated, Mr. Reardon earns $614,870.00 per year. The highest earning executive at Ligand Pharmaceuticals is Mr. Matthew E. Korenberg, President & COO, who commands a salary of $831,770.00 per year. Learn More on Andrew Reardon's salary.

How do I contact Andrew Reardon?

The corporate mailing address for Mr. Reardon and other Ligand Pharmaceuticals executives is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. Ligand Pharmaceuticals can also be reached via phone at (858) 550-7500 and via email at investors@ligand.com. Learn More on Andrew Reardon's contact information.

Has Andrew Reardon been buying or selling shares of Ligand Pharmaceuticals?

Andrew Reardon has not been actively trading shares of Ligand Pharmaceuticals within the last three months. Most recently, Andrew Reardon sold 2,000 shares of the business's stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $99.60, for a transaction totalling $199,200.00. Following the completion of the sale, the insider now directly owns 22,534 shares of the company's stock, valued at $2,244,386.40. Learn More on Andrew Reardon's trading history.

Who are Ligand Pharmaceuticals' active insiders?

Ligand Pharmaceuticals' insider roster includes Todd Davis (CEO), Octavio Espinoza (CFO), Matthew Foehr (COO), Nancy Gray (Director), John Higgins (CEO), John Kozarich (Director), John LaMattina (Director), Andrew Reardon (Chief Legal Officer), and Stephen Sabba (Director). Learn More on Ligand Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Ligand Pharmaceuticals?

During the last year, Ligand Pharmaceuticals insiders bought shares 1 times. They purchased a total of 2,500 shares worth more than $243,475.00. During the last year, insiders at the biotechnology company sold shares 16 times. They sold a total of 86,526 shares worth more than $8,524,068.88. The most recent insider tranaction occured on March, 4th when CFO Octavio Espinoza sold 5,000 shares worth more than $575,150.00. Insiders at Ligand Pharmaceuticals own 5.9% of the company. Learn More about insider trades at Ligand Pharmaceuticals.

Information on this page was last updated on 3/4/2025.

Andrew Reardon Insider Trading History at Ligand Pharmaceuticals

See Full Table

Andrew Reardon Buying and Selling Activity at Ligand Pharmaceuticals

This chart shows Andrew Reardon's buying and selling at Ligand Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$500k$0$500kTotal Insider BuyingTotal Insider Selling

Ligand Pharmaceuticals Company Overview

Ligand Pharmaceuticals logo
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
Read More

Today's Range

Now: $96.67
Low: $94.77
High: $102.70

50 Day Range

MA: $111.88
Low: $96.67
High: $122.23

2 Week Range

Now: $96.67
Low: $67.72
High: $129.90

Volume

159,976 shs

Average Volume

123,017 shs

Market Capitalization

$1.86 billion

P/E Ratio

38.51

Dividend Yield

N/A

Beta

1.07